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Abstract: Plitidepsin is a cyclic depsipeptide of marine origin in clinical development in 
cancer  patients.  Previously,  some  depsipeptides  have  been  linked  to  increased  cardiac 
toxicity. Clinical databases were searched for cardiac adverse events (CAEs) that occurred 
in  clinical  trials  with  the  single-agent  plitidepsin.  Demographic,  clinical  and 
pharmacological variables were explored by univariate and multivariate logistic regression 
analysis. Forty-six of 578 treated patients (8.0%) had at least one CAE (11 patients (1.9%) 
with plitidepsin-related CAEs), none with fatal outcome as a direct consequence. The more 
frequent CAEs were rhythm abnormalities (n = 31; 5.4%), mostly atrial fibrillation/flutter 
(n = 15; 2.6%). Of note, life-threatening ventricular arrhythmias did not occur. Myocardial 
injury events (n = 17; 3.0%) included possible ischemic-related and non-ischemic events. 
Other  events  (miscellaneous,  n  =  6;  1.0%)  were  not  related  to  plitidepsin.  Significant 
associations were found with prostate or pancreas cancer primary diagnosis (p = 0.0017), 
known baseline cardiac risk factors (p = 0.0072), myalgia present at baseline (p = 0.0140), 
hemoglobin levels lower than 10 g/dL (p = 0.0208) and grade ≥2 hypokalemia (p = 0.0095). 
Treatment-related  variables  (plitidepsin  dose,  number  of  cycles,  schedule  and/or  total 
cumulative  dose)  were  not  associated.  Electrocardiograms  performed  before  and  after 
plitidepsin administration (n = 136) detected no relevant effect on QTc interval. None of 
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the pharmacokinetic parameters analyzed had a significant impact on the probability of 
developing a CAE. In conclusion, the most frequent CAE type was atrial fibrillation/atrial 
flutter, although its frequency was not different to that reported in the age-matched healthy 
population, while other CAEs types were rare. No dose-cumulative pattern was observed, 
and  no  treatment-related  variables  were  associated  with  CAEs.  Relevant  risk  factors 
identified were related to the patient’s condition and/or to disease-related characteristics 
rather than to drug exposure. Therefore, the current analysis supports a safe cardiac risk 
profile for single-agent plitidepsin in cancer patients.  
Keywords: plitidepsin; cardiac toxicity; single agent; chemotherapy; cancer 
 
1. Introduction 
The use of multimodality treatment, including surgery, chemotherapy, radiotherapy, and targeted 
therapies has significantly decreased cancer-related mortality. As more oncological patients now have 
a longer life expectancy, treatment-related comorbidity and its prevention has become an important 
issue  in  cancer  treatment.  Cardiac  disease  in  cancer  patients  is  common  and  can  be  due  to  the 
malignancy itself, co-morbidities like age or pre-existing heart disease, or cardiotoxic chemotherapeutic 
agents. In fact, cardiac toxicity is one of the most worrisome side effects of anticancer therapy because 
the gain in life expectancy obtained with chemotherapy might be counter-balanced by a detrimental 
effect  in the  quality of  life of the  patients, or even lead to an increased mortality  due to cardiac 
problems. Several well-established and widely used anticancer agents have been associated with an 
increased risk of cardiac toxicity: Anthracyclines, fluoropyrimidines, etoposide, high-dose alkylating 
agents,  interferon,  interleukin-2,  taxanes,  monoclonal  antibodies  (trastuzumab,  bevacizumab)  and 
tyrosine kinase inhibitors (sunitinib, sorafenib) among others [1,2]. Nevertheless, their mechanisms 
(known or unknown) of inducing cardiac toxicity are different.  
The most notable chemotherapy-related cardiac toxicity is myocardial damage, which may lead to 
impaired  cardiac  function and  overt  congestive  heart failure. This  type  of cardiotoxicity has  been 
observed in patients treated with anthracyclines or high doses of alkylating agents, and is known as 
type I chemotherapy-related cardiac dysfunction (i.e., it is present from the earliest administration of 
the drug) [3]. Type II chemotherapy-related cardiac dysfunction, characterized by reversibility and 
lack of dependence on dose or re-exposure to the agent, is not associated with myocyte damage and 
has been observed with the administration of trastuzumab or alemtuzumab [4–6]. Other antineoplastic 
agents  (anthracyclines,  5-fluorouracil,  some  platinum  compounds,  multitargeted  tyrosine-kinase 
inhibitors, anti HER-2, anti-vascular endothelial growth factor (VEGF), vascular disruption agents and 
histone deacetylase inhibitors (HDACIs)) may affect QT interval duration in the electrocardiogram [7]. 
This effect is also observed with other different agents that are widely used among cancer patients, 
such as concomitant medications to reduce the side effects of chemotherapy, particularly, some serotonin 
receptor antagonist antiemetic agents [8]. Fortunately, cardiac side effects remain uncommon with 
most chemotherapeutic agents, and several preventive or protective strategies are currently available [9]. 
Cardiac toxicity resulting in myocardial dysfunction can become apparent immediately or long after Mar. Drugs 2011, 9  
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the end of therapy, and often is irreversible. Therefore, early and accurate detection of cardiac injury is 
crucial because it can lead to early therapeutic interventions. Close and accurate monitoring of cardiac 
function is important for early detection of cardiac dysfunction during clinical development of new 
anticancer therapies, which might lead to timely-appropriate preventive measures. 
Aplidin
® (plitidepsin) is a cyclic depsipeptide originally isolated from the Mediterranean tunicate 
Aplidium albicans and currently produced by chemical synthesis [10]. Plitidepsin has been proven to 
be  active  against  several  human  malignant  cell  lines  both  in  vitro  and  in  vivo  at  nanomolar 
concentration ranges [11]. The primary mode of action of plitidepsin has not been fully elucidated, 
though evidence available suggests that plitidepsin induces oxidative stress, which increases levels of 
cell membrane phospholipid and DNA oxidation [12], decreases intracellular levels of glutathione and 
activates  the  Rac1-JNK  pathway,  thereby  resulting  in  both  caspase-dependent  and  -independent 
cellular  apoptosis  [13–15].  In  several  preclinical models,  plitidepsin has  also  been shown to  have 
antiangiogenic properties, mainly characterized by inhibition of the expression of different angiogenic 
genes, including VEGF and its receptor (VEGFR-1) [16–19]. Plitidepsin has been extensively studied 
as single-agent chemotherapy in phase I and II clinical trials [20–30], and clinically relevant antitumor 
activity has been observed in a wide-spectrum of solid as well as hematological malignancies such as 
malignant melanoma [25], multiple myeloma [29], peripheral T-cell lymphoma [30] and renal cell 
carcinoma  [23].  Plitidepsin  is  currently  being  explored  in  a  pivotal  randomized  phase  III  trial 
(ADMYRE study) conducted in patients with relapsed/refractory multiple myeloma who have failed 
standard available therapies. 
Plitidepsin has neither shown cardiac toxicity during preclinical/toxicology studies nor has been 
reported in early phase I clinical trials [20–22]. However, other chemically-related compounds such as 
depsipeptides under clinical evaluation (e.g., FK228, and HDACI) have shown QTc prolongation, 
moderate ventricular tachycardia and sudden death attributed to possible fatal ventricular arrhythmia in 
phase II clinical trials [31,32]. Although cardiotoxic effects of FK228 have already been identified in 
preclinical  toxicology  studies  in  dog  [31],  its  ability  to  induce  cardiac  toxicity  appears  to  be 
heterogeneous  and  may  vary  based  on  the  patient  population  [33].  Electrocardiogram  (ECG) 
abnormalities may be a class effect, as this has been reported with other HDACI inhibitors such as 
LBH589 or LAQ824 [33]. 
As other cyclic depsipeptides have been linked to increased cardiac toxicity, the current analysis 
evaluated the cardiac safety profile of plitidepsin based on the safety information on cardiac adverse 
events (CAEs) that occurred during clinical trials to evaluate plitidepsin as single-agent chemotherapy 
in adult patients with advanced solid tumors or hematological malignancies.  
2. Patients and Methods 
Clinical trials included in this cardiac safety analysis were 4 phase I and 14 phase II studies evaluating 
plitidepsin as single-agent chemotherapy in a total of 578 adult patients (see details in Table 1). All 
available  information  on CAEs was  retrieved  from Pharma Mar’s  internal  Pharmacovigilance  and 
Clinical  Trials  databases.  The  reviewed  sources  of  information  were  Case  Report  Forms  (CRFs), 
serious  adverse  event  (SAE)  reports,  follow-up  reports  and  supplementary  reports  attached  or Mar. Drugs 2011, 9  
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requested. Median follow-up was 12.0 months (95% CI, 7.6–13.8) for phase I trials and 12.3 months 
for phase II trials (95% CI, 11.0–13.7). Cutoff for data analysis was 20 November 2008.  
Table 1. Cardiac monitoring and pharmacokinetic data available in clinical trials included 
in this cardiac safety analysis (n = 18 studies). 
Study Phase  Main indication  Pts 
Prospective cardiac monitoring 
PK 
data 
Ref. 
Troponin  LVEF 
CPK-
MB 
ECG 
monitoring 
Intensive ECGs 
monitoring 
1  I  Solid tumors or lymphomas  62  Yes  No  No  Yes  No  Yes  [34] 
2  I  Solid tumors or lymphomas  48  No  No  Yes  Yes  No  Yes  [22] 
3  I  Solid tumors or lymphomas  67  No  No  No  Yes  No  Yes  [20] 
4  I  Solid tumors or lymphomas  37  No  No  No  Yes  No  Yes  [21] 
5  II  Renal or colorectal cancer  81  No  No  Yes  No  No  Yes  [23] 
6  II  Medullary thyroid cancer  16  No  Yes  No  Yes  No  Yes  [27] 
7  II  Pancreatic cancer  19  No  Yes  No  Yes  No  No  NA 
8  II  NSCLC  21  No  No  No  Yes  No  No  [28] 
9  II  Urothelial cancer  21  No  Yes  Yes  Yes  No  Yes  [26] 
10  II  SCLC  19  No  Yes  Yes  Yes  No  Yes  [24] 
11  II  Second-line melanoma  37  No  Yes  Yes  Yes  No  Yes  [25] 
12  II  Head and neck cancer  10  No  No  Yes  Yes  No  No  NA 
13  II  Refractory androgen-
independent prostate cancer 
8  Yes  Yes  Yes  Yes  Yes  Yes  NA 
14  II  Indolent Non-Hodgkin’s 
lymphoma 
8  Yes  Yes  Yes  Yes  No  No  NA 
15  II  Aggressive non-Hodgkin’s 
lymphoma 
48  Yes  Yes  Yes  Yes  Yes  Yes  [30] 
16  II  Multiple myeloma  51  Yes  Yes  Yes  Yes  Yes  Yes  [29] 
17  II  Acute lymphoblastic leukemia  17  Yes  Yes  Yes  Yes  No  Yes  NA 
18  II  First-line melanoma  8  Yes  Yes  Yes  Yes  Yes  No  NA 
Total 
(%) 
578 
7 
(38.9%) 
11 
(61.1%) 
12 
(66.7%) 
17 
(94.4%) 
4 
(23.5%) 
13 
(72.2%) 
 
CPK-MB:  creatine  phosphokinase-MB  fraction;  ECG:  electrocardiogram;  LVEF:  left  ventricular  ejection  fraction;  
NA: not available; NSCLC: non-small cell lung cancer; PK: pharmacokinetic; Pts: patients; SCLC: small cell lung cancer. 
All adverse events (AEs) with preferred terms of the Medical Dictionary for Regulatory Activities 
(MedDRA)  that  could  be  potentially  classified  as  cardiac  were  evaluated.  Additionally,  events 
included in other systems as well in those patients with any vascular risk associated (prior history or 
within the trial) were also reviewed. Laboratory data were also reviewed in those cases with grade 3/4 
creatine phosphokinase increase and/or troponin (troponin C or troponin I) elevations. Patients’ prior 
history  and  baseline  information  were  searched  for  any  associated  vascular  risk  (diabetes, 
hypercholesterolemia, hypertension, smoking, prior myocardial infarction or angina, etc.). All events 
retrieved  using  the  aforementioned  criteria  were  reviewed  to  identify  and  exclude  from  analysis 
potential CAEs due to obvious cancer-related symptoms (e.g., sinusal tachycardia in anemic patients, 
chest pain obviously related to tumor involvement of the chest). CAEs were divided into three groups: 
“rhythm abnormalities” (including regular and irregular supraventricular thacychardia), “myocardial Mar. Drugs 2011, 9  
 
 
1011 
injury”  (including  possible  ischemic-related  events  and  other  myocardial  events,  such  as  cardiac 
failure, cardiomegaly, cardiomyopathy, ejection fraction decrease, etc.), and “miscellaneous” (CAEs 
that did not fit into any of the other two categories). The information obtained was tabulated and a 
descriptive analysis is reported here. 
To avoid potential bias, candidate variables were explored by univariate analysis regardless of the 
relationship attributed to the CAE with plitidepsin by the investigators (related, unrelated or unknown). 
Univariate logistic regression was used to study the relationship between the occurrence of a CAE and 
categorical  and  continuous  patient  and  disease  characteristics,  and  other  observed  toxicities  or 
laboratory abnormalities. Those variables found to be clinically relevant and/or statistically significant 
(or of borderline significance) in this analysis were further assessed as covariates in a multivariate 
analysis  using  logistic  regression  with  stepwise  variable  selection  and  multiple  correspondence 
analysis methods.  
Selected ECG variables (Bazett’s corrected QT interval (QTc) and heart rate (HR)) were analyzed 
in patients with paired ECG data (i.e., available before and after plitidepsin infusion, n = 136).  
Pharmacokinetic (PK) data available from individual clinical trials (four phase I studies and nine 
phase II studies; see details in Table 1) and/or simulated data using population PK analyses were correlated 
with the occurrence of CAEs. In the individual studies, doses ranged from 0.13 to 8.00 mg/m
2, and 
were administered as 1 h or 24 h infusion weekly, 3 h or 24 h infusion bi-weekly, or 1 h infusion for 
5 consecutive days every 3 weeks. To evaluate the potential relationship between blood plitidepsin 
concentrations and QTc and HR values, a total of 90 patients who had ECGs performed during treatment 
with plitidepsin and PK data during first infusion were analyzed. The plitidepsin concentration at the 
time when the ECG had been obtained was calculated using the whole blood plitidepsin concentration 
at the ECG times in which they were simulated taking the individual Bayesian PK parameters of the 
final  population  PK  model  and  considering  the  real  treatment  history  of  each  patient.  In  total, 
411 patients and 5585 plitidepsin concentration measurements (including 2900 blood and 2685 plasma 
concentrations) were pooled in the population PK analysis. An open, 3-compartment disposition model 
with linear elimination and linear distribution from the central compartment to peripheral compartments 
was used to describe the PK of plitidepsin in plasma. Between and within subject variabilities were 
assumed to be log-normally distributed. PK exposure parameters (maximum concentration in plasma 
(Cmax)  and  area  under  the  curve  (AUC)  from  day  0  to  day  28)  and  other  dose-independent  PK 
parameters  (clearance,  half-life,  etc.)  were  used  to  evaluate  the  relationship  between  patient  PK 
characteristics and the appearance of CAEs. For the statistical analysis of the relationship between the 
exposure parameters and the development or not of a CAE, a logistic regression model was used to 
analyze the incidence of the event. To avoid loss of cases with respect to other covariates included in 
this  multivariate  analysis,  the  PK  parameters  of  the  167  patients  that  did  not  have  PK  data  were 
calculated and included using the real dosing and the typical PK population parameters [35]. 
3. Results 
Forty-six of the 578 patients (8.0%) treated with plitidepsin as single agent had at least one CAE 
(Table 2). The majority of these CAEs (37 of 46 patients) occurred in phase II trials, particularly in 
two  studies  evaluating  plitidepsin  in  patients  with  pancreatic  and  prostate  cancer.  Eleven  patients Mar. Drugs 2011, 9  
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(1.9%) had 15 CAEs related to plitidepsin. These CAEs consisted of palpitations (n = 4), chest pain  
(n = 2), and supraventricular tachycardia, tachycardia, atrial fibrillation, atrial flutter, cardiac failure, 
acute cardiomyopathy, change in ECG, ECG QT prolonged, and ejection fraction decreased (n = 1 each). 
None of the patients who experienced a CAE (whether related, unrelated or unknown) had a fatal 
outcome as a direct consequence. 
Table 2. Cardiac adverse events reported with plitidepsin treatment. 
 
Patients 
treated 
Patients with cardiac event 
(regardless of relationship) 
Patients with cardiac event 
related to plitidepsin 
Patients with cardiac event 
of unknown causality * 
Total phase I  214  9 (4.2%)  2 (0.9%)  2 (0.9%) 
Total phase II  364  37 (10.2%)  9 (2.5%)  14 (3.8%) 
Total  578  46 (8.0%)  11 (1.9%)  16 (2.8%) 
Data shown are n (%) of patients; A patient may have more than one cardiac adverse event (CAE); The 
median number of plitidepsin-related CAEs was 1 (range 1–2), and the median number of CAEs (regardless 
of relationship) was 1 (range 1–3). Four patients had ≥2 plitidepsin-related CAEs; 14 patients had ≥2 CAEs 
(regardless of relationship); * Relationship with plitidepsin unknown. 
Classification of CAEs is shown in Table 3. The most frequent type was rhythm abnormalities  
(n = 31; 5.4%), with irregular supraventricular tachycardia (n = 15; 2.6%) being the most common 
(atrial fibrillation/flutter accounting for most cases). Univariate analysis showed that patients without 
known cardiac risk factors or relevant cardiac concomitant medication at baseline, lower performance 
status,  absence  of  significant  myalgia  at  baseline,  normal  or  low  body  mass  index,  and  higher 
hemoglobin  levels  during  treatment  were  at  a  significantly  lower  risk  of  experiencing  rhythm 
abnormalities.  Remarkably,  no  treatment-related  exposure  variables  were  significant  in  predicting 
occurrence of these events. 
Table 3. Cardiac adverse events (regardless of relationship) reported with plitidepsin treatment. 
  All studies (n = 578)  Phase II studies (n = 364) 
Group/Subgroup/Terms *  Patients (%)  Patients (%) 
Rhythm Abnormalities  31 (5.4%)  25 (6.9%) 
Regular Supraventricular Tachycardia  6 (1.0%)  1 (0.3%) 
Sinus tachycardia  1 (0.2%)  1 (0.3%) 
Supraventricular arrhythmia  1 (0.2%)  0 (0.0%) 
Supraventricular tachycardia  1 (0.2%)  0 (0.0%) 
Tachycardia  3 (0.5%)  0 (0.0%) 
Irregular Supraventricular Tachycardia  15 (2.6%)  14 (3.8%) 
Atrial fibrillation  11 (1.9%)  10 (2.7%) 
Atrial flutter  5 (0.9%)  5 (1.4%) 
Heart rate irregular  1 (0.2%)  1 (0.3%) 
Other Rhythm Abnormalities  13 (2.2%)  13 (3.6%) 
Arrhythmia   1 (0.2%)  1 (0.3%) 
Atrioventricular block  1 (0.2%)  1 (0.3%) 
Change in electrocardiogram  1 (0.2%)  1 (0.3%) 
Electrocardiogram QT prolonged  5 (0.9%)  5 (1.4%) 
Palpitations  6 (1.0%)  6 (1.6%) Mar. Drugs 2011, 9  
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Table 3. Cont. 
Myocardial Injury  17 (3.0%)  14 (3.8%) 
Possible Ischemic Related  10 (1.7%)  8 (2.2%) 
Acute myocardial infarction  1 (0.2%)  1 (0.3%) 
Cardiac troponin I increased  1 (0.2%)  1 (0.3%) 
Chest pain  4 (0.7%)  2 (0.5%) 
Electrocardiogram ST-T change  1 (0.2%)  1 (0.3%) 
Myocardial ischemia  3 (0.5%)  3 (0.8%) 
Other Myocardial Injury  7 (1.2%)  6 (1.6%) 
Cardiac failure  3 (0.5%)  2 (0.5%) 
Cardiomegaly  1 (0.2%)  1 (0.3%) 
Cardiomyopathy  2 (0.3%)  2 (0.5%) 
Ejection fraction decreased  1 (0.2%)  1 (0.3%) 
Miscellaneous Cardiac Adverse Events  6 (1.0%)  3 (0.8%) 
Cardiac amyloidosis  1 (0.2%)  1 (0.3%) 
Hypertension  1 (0.2%)  0 (0.0%) 
Hypotension  2 (0.3%)  2 (0.5%)  
Pericardial effusion  3 (0.5%)  1 (0.3%) 
Ventricular hypokinesia  1 (0.2%)  1 (0.3%) 
Total Adverse Events  46 (8.0%)  37 (10.2%) 
* A patient may have more than one cardiac adverse event (CAE). The median number of plitidepsin-related 
CAEs was 1 (range 1–2), and the median number of CAEs (regardless of relationship) was 1 (range 1–3). 
Four patients had ≥2 plitidepsin-related CAEs; 14 patients had ≥2 CAEs (regardless of relationship). 
Myocardial injury events were relatively rare (n = 17; 3.0%). Chest pain (n = 4; 0.7%), myocardial 
ischemia (n = 3; 0.5%) and cardiac failure (n = 3; 0.5%) were the most common. As mentioned above, 
none  of  these  CAEs  had  fatal  outcome  as  a  direct  consequence.  Univariate  analysis  showed  
patient-dependant and disease-dependant variables, such as older age (no events occurred in patients 
under  45  years),  prostate  or  pancreatic  cancer  primary  diagnosis,  higher  bilirubin  levels  during 
treatment,  lower  creatinine  clearance  during  treatment,  and  at  least  grade  2  hypokalemia  during 
treatment) as significantly correlated with the occurrence of myocardial injury events.  
The  miscellaneous  category  (n  =  6;  1.0%)  included  all  other  CAEs.  The  most  reported  were 
pericardial effusion (n = 3; 0.5%) and hypotension (n = 2; 0.3%). None of these events was recorded as 
related to plitidepsin in the databases. Patients with hemoglobin values lower than 10 g/dL during 
treatment, and those with prior history of mediastinal radiotherapy, were significantly more likely to 
experience events grouped in this category. 
Multivariate analysis showed 5 significant variables significantly associated with CAEs: Prostate or 
pancreatic cancer primary diagnosis (p = 0.0017; odds ratio (OR) = 4.217); known baseline cardiac risk 
factors (p = 0.0072; OR = 3.034); grade ≥2 hypokalemia during treatment (p = 0.0095; OR = 3.851); 
myalgia present at baseline (p = 0.0140; OR = 5.015), and low hemoglobin values (<10 g/dL) during 
treatment (p = 0.0208; OR = 2.195) (Table 4). Of note, all these five variables are patient-related or 
disease-related characteristics. 
The  spatial  distribution  according  to  a  multiple  correspondence  analysis  of  the  values  of  the 
5 significant variables selected in the logistic multivariate regression model (Figure 1) predicted the 
absence of CAEs in an accurate way: All  protective  categories  (tumors  different  than prostate or Mar. Drugs 2011, 9  
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pancreatic cancer; grade 0–1 hypokalemia, no myalgia at baseline, no cardiac risk or relevant concomitant 
medication at baseline, and hemoglobin ≥10 g/dL) were grouped around the “no-CAE” area. 
Table 4. Overall multivariate analysis of variables associated to cardiac adverse events 
with plitidepsin treatment. 
Parameter *  Reference value  DF  Estimate 
Standard 
error 
Wald 
chi-square 
p-value **  OR  95% CI 
Tumor type 
Prostate or 
pancreatic cancer 
1  1.4392  0.4585  9.8519  0.0017  4.217  1.717  10.360 
Cardiac risk and 
relevant concomitant 
medication at baseline 
Presence  1  1.1100  0.4131  7.2192  0.0072  3.034  1.350  6.819 
Hypokalemia (worst 
per patient) 
Grade ≥2  1  1.3484  0.5200  6.7249  0.0095  3.851  1.390  10.671 
Myalgia (at baseline)  Presence  1  1.6124  0.6564  6.0349  0.0140  5.015  1.385  18.154 
Hemoglobin (worst 
per patient) 
<10 g/dL  1  0.7861  0.3402  5.3406  0.0208  2.195  1.127  4.275 
*  Three  variables  (hemoglobin  <10  g/dL,  hypokalemia  grade  ≥2  and  presence  of  cardiac  risk/relevant  concomitant 
medication at baseline) lost statistical significance when unrelated CAEs were excluded from the multivariate analysis, 
possibly due to the low number of events and to the added new category (related, unknown and no CAE). Nevertheless, 
overall results were similar, thus showing that causal relationship assigned to the events was not a determinant factor;  
** Wald Chi Square test (ordered by decreasing significance); CAE: cardiac adverse event; CI: confidence intervals;  
DF: degrees of freedom; OR: odds ratio. 
Figure 1. Multiple correspondence analysis (overall); Hb: Hemoglobin; WPP: worst per patient. 
 
Electrocardiograms performed before and after plitidepsin administration showed no relevant effect 
on QTc interval and HR (Table 5). The mean (SD) increase in QTc values was 2.51 (32.99) msec in all 
patients with available ECG (n = 136), and 4.85 (31.66) msec in patients with a CAE (n = 20). The Mar. Drugs 2011, 9  
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mean (SD) increase in HR values was 3.39 (9.92) bpm in all patients and 6.05 (9.76) bpm in patients 
with a CAE. 
An additional analysis was performed to evaluate a potential relationship between whole blood 
plitidepsin concentrations and QTc. For this evaluation, all ECGs performed during treatment with 
plitidepsin were considered (total of 263 ECGs), and not only those ECGs with a pair before/after each 
infusion  (Figure  2).  No  apparent  relationship  was  found  between  plitidepsin  concentrations  and 
QTc interval. 
Table 5. Bazett’s corrected QT interval (QTc) and heart rate (HR) values of all patients 
evaluated and grouped by the presence and type of cardiac adverse event. 
Group 
(number of pairs) 
QTc (msec) 
Pre-infusion 
QTc (msec) 
Post-infusion 
ΔQTc (msec) 
HR (bpm) 
Pre-Infusion 
HR (bpm) 
Post-Infusion 
ΔHR 
(bpm) 
All (n = 136) *  426.77 (38.78)  429.28 (40.25)  2.51 (32.99)  79.07 (15.33)  82.46 (13.17)  3.39 (9.92) 
No cardiac event (n = 116)  424.88 (40.06)  426.98 (41.18)  2.10 (33.33)  79.92 (15.53)  82.86 (13.53)  2.94 (9.91) 
Cardiac event (n = 20)  437.75 (28.65)  442.60 (32.09)  4.85 (31.66)  74.05 (13.39)  80.10 (10.87)  6.05 (9.76) 
Rhythm abnormalities (n = 18) 439.44 (29.79)  442.67 (33.79)  3.22 (32.89)  75.44 (13.39)  80.44 (11.30)  5.00 (9.70) 
Myocardial injury (n = 4)  429.00 (29.15)  437.50 (15.20)  8.50 (21.79)  68.75 (10.34)  77.75 (12.55)  9.00 (9.90) 
Data shown are mean (SD); * Only ECGs performed within 4 h after the end of the infusion are included because ECGs 
performed later were onsidered to not reflect the real QTc increase potentially caused by plitidepsin. A total of 136 pairs 
of measurements were available, corresponding to the same number of plitidepsin infusions; Bpm: beats per minute; 
ECG: electrocardiogram; HR: heart rate; SD: standard deviation. 
Figure  2.  Simulated  whole  blood  plitidepsin  concentration  vs.  Bazett’s  corrected  QT 
interval (QTc) interval (left graph) and heart rate (right graph) for patients without and with 
a cardiac event. The whole blood plitidepsin concentration at the ECG times was simulated 
taking the individual post-hoc PK parameters of population PK model and considering the 
real treatment history of each patient. Lines are the regression lines for patients without (blue 
line) and with a cardiac event (red line). ECG: electrocardiogram; PK: pharmacokinetic. 
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(n = 375) had a whole blood Cmax and AUC0–28day of 58.8 ng/mL and 3374 h· ng/mL, respectively, 
while  those  with  a  CAE  (n  =  36)  had  a  whole  blood  Cmax  and  AUC0–28day  of  61.0  ng/mL  and 
3236 h· ng/mL, respectively (Table 6). 
The results of the logistic regression analyses are shown in Table 7. The ORs for all analyses were 
very close to 1; this indicates that the contribution of the evaluated PK parameters to the probability of 
developing a CAE was very low. None of these comparisons was statistically significant. 
Table 6. Mean (SD) plitidepsin pharmacokinetic parameters by category of the cardiac 
adverse event. AUC: area under the curve; Cmax: maximum plasma concentration. 
Group (number of patients)  Cmax (ng/mL)  AUC0–28day (h· ng/mL) 
No Cardiac adverse Event (n = 375)  58.8 (38.8)  3374 (4336) 
Cardiac Adverse Event (n = 36)  61.0 (27.9)  3236 (2955) 
Rhythm Abnormalities (n = 25)  61.5 (29.8)  3435 (3372) 
Regular supraventricular tachycardia (n = 6)  57.2 (23.1)  5277 (3997) 
Irregular supraventricular tachycardia (n = 12)  63.7 (34.6)  3197 (3640) 
Other rhythm abnormalities (n = 10)  56.8 (26.2)  2064 (1449) 
Myocardial Injury (n = 11)  69.5 (28.2)  4077 (3653) 
Possible ischemic related (n = 7)  72.2 (28.8)  3668 (1696) 
Other myocardial injury (n = 4)  64.7 (30.6)  4791 (6136) 
Miscellaneous Cardiac Adverse Event (n = 7)  54.5 (19.7)  2645 (1672) 
Table  7.  Results  of  the  logistic  regression  analysis  evaluating  the  effect  of  Cmax  and  
AUC0–28day on the probability of having a cardiac adverse event. 
Group (number of patients)  PK parameter  Estimate (β)  SE  OR  95% CI  p value * 
Cardiac Adverse Event (n = 36) 
Cmax  0.001480  0.004360  1.001  0.993  1.010  0.7346 
AUC0–28day  −0.000008  0.000045  1.000  1.000  1.000  0.8521 
Rhythm Abnormalities (n = 25) 
Cmax  0.001760  0.005030  1.002  0.992  1.012  0.7264 
AUC0–28day  0.000003  0.000047  1.000  1.000  1.000  0.9449 
Regular supraventricular tachycardia 
(n = 6) 
Cmax  −0.001090  0.0112  0.999  0.977  1.021  0.9219 
AUC0–28day  0.000049  0.000049  1.000  1.000  1.000  0.3153 
Irregular supraventricular tachycardia 
(n = 12) 
Cmax  0.002890  0.00662  1.003  0.990  1.016  0.6624 
AUC0–28day  −0.000010  0.000076  1.000  1.000  1.000  0.8889 
Other rhythm abnormalities (n = 10) 
Cmax  −0.001420  0.0088  0.999  0.982  1.016  0.8720 
AUC0–28day  −0.000230  0.000202  1.000  0.999  1.000  0.2625 
Myocardial Injury (n = 11) 
Cmax  0.005440  0.005950  1.005  0.994  1.017  0.3605 
AUC0–28day  0.000027  0.000051  1.000  1.000  1.000  0.5978 
Possible ischemic related (n = 7) 
Cmax  0.006280  0.00684  1.006  0.993  1.020  0.3581 
AUC0–28day  0.000013  0.000075  1.000  1.000  1.000  0.8575 
Other myocardial injury (n = 4) 
Cmax  0.003340  0.0108  1.003  0.982  1.025  0.7580 
AUC0–28day  0.000041  0.000066  1.000  1.000  1.000  0.5301 
Miscellaneous Cardiac Event (n = 7) 
Cmax  −0.003290  0.0111  0.997  0.975  1.019  0.7667 
AUC0–28day  −0.000070  0.000155  1.000  1.000  1.000  0.6470 
* Probability from a Wald Chi Square test. The control arm for all analyses was the population without cardiac event and 
with PK data (n = 375); AUC: area under the curve; CI: confidence interval; Cmax: maximum plasma concentration;  
OR: odds ratio; PK: pharmacokinetic; SE: standard error. Mar. Drugs 2011, 9  
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4. Discussion 
Plitidepsin, a cyclic depsipeptide of marine origin, is an investigational drug currently in clinical 
development as a single agent as well as in combination with other anticancer agents for the treatment 
of  different  solid  tumors  and  hematological  malignancies.  Plitidepsin  did  not  show  a  cardiotoxic 
profile in preclinical/toxicology studies, which involved both in vitro studies (HERG assay and study 
using Purkinje fibers) and an in vivo study in the dog, as well as a exploratory study of the cardiac 
effects  of  escalating  doses  of  plitidepsin  in  a  guinea  pig  Langendorff  preparation  [36].  CAEs  in 
plitidepsin trials were relatively rare (affecting 8% of the patients) and the different categories of CAEs 
evaluated had frequencies lower than 3%; therefore, they are unlikely to share a common pathogenesis 
and/or  common  predisposing  factors  (e.g.,  atrial  fibrillation  and  myocardiopathy  or  pericardial 
effusion). The current comprehensive safety analysis shows that CAEs occurred in plitidepsin trials 
with a median follow-up of about one year were clinically heterogeneous, with the most frequent CAE 
type being non-life threatening rhythm alterations (mostly atrial fibrillation/flutter). It should be noted 
that the frequency of these rhythm abnormalities (5.4%) was not different to what is actually reported 
in the age-matched healthy population [37–39].  
Rhythm abnormalities appeared to be characterized by random onset during treatment and were 
usually reversible even without treatment discontinuation. Relevant predisposing factors identified in 
univariate and multivariate analyses were mostly related with patient’s baseline characteristics and 
disease-related  characteristics  rather  than  with  drug  exposure  or  treatment-related  characteristics. 
Rhythm abnormalities occurred more frequently in patients with predisposing cardiac factors, with 
lower hemoglobin values than 10 g/dL at some point during treatment and poor performance status at 
baseline. The higher incidence observed in phase II studies (6.9% vs. 5.4% in all studies) may be 
explained by the introduction of systematic screening measures in all phase II studies since 2006, with 
extensive serial ECGs evaluations before and after plitidepsin infusions that could detect events that 
otherwise  would  have  been  missed.  This  higher  incidence  may  have  also  been  caused  by  two 
individual phase II studies in specific solid tumor types (prostate and pancreatic cancer) that represent 
a particularly frail and susceptible subpopulation of patients. Remarkably, potentially life-threatening 
arrhythmias (e.g., ventricular arrhythmias) did not occur within plitidepsin trials.  
Events of the myocardial injury type (whether ischemic or not) were relatively rare and frequency 
in phase II studies was not increased significantly compared to phase I studies despite the extensive 
monitoring measures implemented. Of note, none of these CAEs had  a fatal outcome  as  a  direct 
consequence. Known increased cardiac risk conditions as well as prior anthracycline treatment were 
not correlated with the occurrence of myocardial injury events; however, more restrictive inclusion 
criteria and better patient selection regarding these factors in all plitidepsin trials since 2006 may have 
had a role in preventing a rising of these events in phase II studies. Age, but not gender, was associated 
with an increased frequency of myocardial injury events. Patients with prostate and pancreatic cancer 
were  significantly  more  likely  to  experience  these  events.  Lower  creatinine  clearance  was  also 
associated with an increased cardiac risk. This alteration is commonly observed in prostate [40,41] and 
pancreatic  cancer  patients  [42],  as  well  as  an  overall  increased  risk  of  thromboembolic  events. 
Particularly  remarkable  with respect to potential associations between  musculoskeletal and cardiac 
toxicity was the lack of a significant association in univariate analyses between relevant musculoskeletal Mar. Drugs 2011, 9  
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related symptoms (n = 332) that plitidepsin is well known to cause (creatine phosphokinase increased 
at baseline or during treatment, muscular weakness, muscle cramps and fatigue) and the occurrence of 
CAEs. Thus, patients who experienced musculoskeletal toxicity while on plitidepsin treatment did not 
show an increased risk of myocardial injury. 
Some laboratory alterations found during treatment (hemoglobin decreases or grade ≥2 hypokalemia) 
were statistically significant in the multivariate analyses. No laboratory alterations at baseline were 
significantly  associated  with  an  increased  risk  of  CAEs,  but  this  is  an  expected  finding  as  study 
inclusion criteria generally excluded patients with extreme laboratory values. Cancer patients with 
anemia are more prone to have arrhythmias, which may trigger the development of further CAEs, such 
as ischemia, or may even be the direct cause of events such as palpitations [43]. Hypokalemia is 
known to be associated with several arrhythmias and QT prolongation [44], but is not commonly 
associated to plitidepsin treatment. The associations with other metabolic disturbances known to cause 
arrhythmias (e.g., hypocalcemia or hyponatremia) were non-significant. Of note, none of the severe 
arrhythmias  more  commonly  associated  with  metabolic  disturbances  (e.g.,  Torsades  de  pointes, 
ventricular arrhythmias and severe QT prolongation) occurred in patients treated with plitidepsin.  
The incidence of cardiotoxicity related to oncological therapy depends on treatment-related factors 
(type of drug, cumulative dose and schedule of administration, combination of potentially cardiotoxic 
drugs, or association with mediastinal radiotherapy), but also on patient-related factors (age, presence 
of cardiovascular risk factors or coexisting cardiac disease, previous mediastinal irradiation, etc.) [45]. 
Some demographic variables are known to be associated with an increased cardiac risk of cardiac 
disease in the general population. The incidence of cardiac disease increases with age, and so does the 
incidence of cancer. The only significant relationship between age and CAEs was found for myocardial 
injury events where, remarkably, no such events occurred in patients younger than 45 years.  
The  results  of  multivariate  analysis,  after  selecting  the  most  significant,  reproducible  and 
representative variables found in univariate analyses, were consistent with those of univariate analyses, 
although,  as  expected  given  the  relatively  low  overall  incidence  of  CAEs,  models  were  more 
representative for predicting patients at very low risk of experiencing these events than for predicting 
patients likely to experience them. The spatial distribution, according to a multiple correspondence 
analysis, of the five variables found significant in the multivariate analysis accurately predicted the 
absence of CAEs in patients with a cancer diagnosis other than prostate or pancreatic cancer, without 
myalgia  at baseline, without known cardiac risks at baseline, with less than grade 2 hypokalemia 
during treatment, and with hemoglobin levels higher than 10 g/dL during treatment. Notably, none of 
these significant variables was related with plitidepsin treatment exposure; this finding is consistent 
with the clinical and the PK analyses. However, a definite conclusion cannot be drawn yet due to the 
relatively small number of patients treated and the relatively low incidence of CAEs observed to date. 
Furthermore, other factors that may have been unnoticed in this analysis might also play a role in the 
occurrence of CAEs. 
A slight mean increase (2.51 ms) was found in the QTc interval after plitidepsin infusion compared 
with the value obtained before the infusion. Plitidepsin concentration did not appear to have an effect 
on the magnitude of the QTc interval. Nevertheless, the analysis presented here has some important 
flaws: lack of uniformity  in the method for measuring QT intervals, absence of  a control for the 
circadian rhythm, and presence of premedication (antiemetics) in all patients known to potentially Mar. Drugs 2011, 9  
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affect QT interval [8]. Therefore, this analysis should be considered an exploratory approach for the 
evaluation of any potential effect of plitidepsin on the QT interval, where no alarming signs have been 
detected so far and no definite conclusions can be drawn. 
Cmax and AUC0–28day were used to evaluate the relationship between patient PK characteristics and 
appearance of CAEs. Based on the real plasma and whole blood concentrations, a population PK 
model was developed to derive the individual post-hoc PK parameters. A whole blood PK profile from 
day 0 to day 28 was simulated taking into account the derived individual post-hoc PK parameters and 
the true treatment history of each patient. This was considered the best way to define a relevant PK 
exposure with the integration of all patients into one analysis. The difficulties encountered were the 
availability of plasma  and whole blood concentrations in different patients (some only had whole 
blood concentrations, others only had plasma concentrations and some had both) and the very different 
schedules of administration used in the clinical trials. The doses given to patients included in the phase 
II studies were those defined as the recommended dose for every schedule. Thus, in the evaluation of 
these patients, the dose-independent parameters (clearance, volume of distribution at steady-state and 
half-life) were also taken into consideration. None of the PK parameters evaluated had a significant 
impact on the probability of developing a CAE, either when all events were analyzed together or when 
the analysis was performed in the different categories for each CAE.  
5. Conclusion 
The CAEs observed in plitidepsin trials are clinically heterogeneous. The most frequent CAE was 
atrial  fibrillation/atrial  flutter,  although  its  incidence  was  not  different  to  that  reported  in  the  
age-matched healthy population. Other CAE types were rare. Relevant predisposing factors identified 
in univariate and multivariate analyses were mostly related with patient’s baseline characteristics and 
disease-related characteristics rather than with drug exposure or treatment-related characteristics, and 
none of the explored PK parameters showed a correlation. No dose-cumulative pattern was observed, 
and no treatment-related variables were associated with CAEs. Therefore, the current analysis with 
data available on 578 adult advanced cancer patients treated with single-agent plitidepsin supports a 
safe cardiac risk profile for this agent. However, although cardiac safety does not seem to be of special 
concern with the available data, comprehensive monitoring measures remain in place and are operative 
in plitidepsin trials to identify any potential cardiac safety risk as early as possible in order to prompt 
and  adequately  manage  any  early  sign  in  patients  exposed  to  plitidepsin.  Preventive  measures  in 
ongoing  trials  with  plitidepsin  include  inclusion  of  patients  with  adequate  hemoglobin  levels  at 
baseline; enrolment of patients with prior exposure to anthracyclines up to a maximal cumulative  
doxorubicin-equivalent  total  dose  of  450  mg/m
2;  extension  of  follow-up  for  LVEF  assessments; 
monitoring of ECG during treatment, and assessment of chronic toxicity. To date, measurement of 
troponin in asymptomatic patients has not proven very useful to identify the cardiovascular risk in 
trials with plitidepsin. All clinical trials included in this analysis had no control arm. A control arm 
without plitidepsin treatment might be the best way to prospectively assess the incidence of CAEs, as 
this may compensate for known and unknown factors present in cancer patients, including concomitant 
treatments, etc. Currently, a phase III randomized trial (ADMYRE study) is ongoing and evaluating 
plitidepsin  in  combination  with  dexamethasone  versus  dexamethasone  alone  in  patients  with Mar. Drugs 2011, 9  
 
 
1020 
relapsed/refractory  multiple  myeloma.  This  trial  will  also  help  to  evaluate  the  effect  of  adding 
plitidepsin  on  cardiac  events  with  respect  to  dexamethasone  monotherapy  in  this  frail  patient 
population, as cardiac safety is intensively and symmetrically monitored in both arms, as well to obtain 
information on the usefulness of troponin assessment in asymptomatic patients. 
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